Mohebi Sepide, Farpour Hamid Reza, Dehghanian Kayvon Seyed, Khoshnazar Sana Sadat
Student Research Committee, Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz Geriatric Research Centre, Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Mediterr J Rheumatol. 2023 Aug 22;34(4):460-468. doi: 10.31138/mjr.220823.aof. eCollection 2023 Dec.
OBJECTIVE/AIM: This study aimed to assess how effective an oral form of Cetylated fatty acids compounds (CFA) is in improving the physical function, pain, and stiffness of individuals suffering from knee osteoarthritis (OA) and how its effectiveness compares to that of Meloxicam, a non-steroidal anti-inflammatory drug (NSAID).
For this parallel-arm randomised clinical trial, 48 adult patients with knee OA were divided into two groups. The intervention group was prescribed 350mg CFA capsule three times per day for 30 days. The control group was given 15mg of Meloxicam, one tablet daily for ten days. Patients were instructed to fill out the Oxford Knee Score (OKS), Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and Visual Analog Scale (VAS). Data were obtained before the administration of the first dose (considered baseline or t), and two (t), four (t), and eight (t) weeks after the final dose of each intervention.
No significant differences were observed in total WOMAC and OKS scores between the two groups at t, t, or t. However, both groups had significant improvements in their OKS, VAS, and total WOMAC scores compared to their baselines (t). No adverse events were noted in the CFA group.
Improvements in pain intensity and overall physical function were reported in the CFA group. Oral CFAs could safely benefit patients with knee OA.
本研究旨在评估口服形式的乙酰化脂肪酸化合物（CFA）在改善膝关节骨关节炎（OA）患者的身体功能、疼痛和僵硬方面的效果，以及其与非甾体抗炎药（NSAID）美洛昔康的效果对比。
在这项平行组随机临床试验中，48名成年膝关节OA患者被分为两组。干预组患者每天服用3次350毫克CFA胶囊，持续30天。对照组患者每天服用1片15毫克美洛昔康，持续10天。患者被要求填写牛津膝关节评分（OKS）、西安大略和麦克马斯特大学骨关节炎指数（WOMAC）以及视觉模拟量表（VAS）。在首次给药前（视为基线或t0）以及每次干预的最后一剂后的2周（t2）、4周（t4）和8周（t8）获取数据。
在t0、t2或t4时，两组之间的WOMAC总分和OKS评分没有显著差异。然而，与基线（t0）相比，两组的OKS、VAS和WOMAC总分均有显著改善。CFA组未观察到不良事件。
CFA组报告了疼痛强度和整体身体功能的改善。口服CFA对膝关节OA患者可能有安全益处。
